Atherosclerosis in Systemic Lupus Erythematosus

被引:12
|
作者
Tobin, Rachel [1 ]
Patel, Nidhi [2 ]
Tobb, Kardie [3 ]
Weber, Brittany [4 ]
Mehta, Puja K. [5 ]
Isiadinso, Ijeoma [5 ]
机构
[1] Emory Univ, Sch Med, Dept Med, Div Cardiol, Atlanta, GA 30322 USA
[2] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA
[3] Cone Hlth Med Grp, Greensboro, NC USA
[4] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Cardiol, Boston, MA USA
[5] Emory Univ, Ctr Heart Dis Prevent, Dept Med, Div Cardiol,Sch Med, Atlanta, GA USA
关键词
Systemic lupus erythematosus; Atherosclerosis; Inflammation and cardiovascular disease; Coronary microvascular disease; Lupus treatment; CORONARY-ARTERY-DISEASE; LOW-DENSITY-LIPOPROTEIN; INDEPENDENT RISK-FACTOR; MYOCARDIAL-INFARCTION; SUBCLINICAL ATHEROSCLEROSIS; ACCELERATED ATHEROSCLEROSIS; MICROVASCULAR DYSFUNCTION; ENDOTHELIAL DYSFUNCTION; CARDIOVASCULAR-DISEASE; PROSPECTIVE COHORT;
D O I
10.1007/s11883-023-01149-4
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Purpose of the ReviewSystemic lupus erythematosus (SLE) patients are at increased risk of cardiovascular disease (CVD) compared to the general population, despite most patients being young females, who are not classically considered to be at high risk for cardiovascular disease using traditional risk assessment tools. The purpose of this review is to discuss the pathophysiology of atherosclerosis in SLE and raise awareness of the relationship between SLE and CVD.Recent FindingsThe increased risk of CVD in SLE patients is multifactorial, due to proatherogenic lipid profiles, immune dysregulation and inflammation, side effects of lupus treatment, and microvascular dysfunction. Conventional CV risk models often underperform in the identification of SLE patients at high risk of atherosclerosis. The use of non-invasive imaging serves as a strategy to identify patients with evidence of subclinical CVD and in the evaluation of symptomatic patients. Identification of subclinical atherosclerosis allows for aggressive management of CV risk factors.SummarySLE patients experience an increased risk of atherosclerotic CVD, which is not solely explained by traditional CV risk factors. It is imperative that clinicians are aware of this association to implement prompt detection and treatment of atherosclerotic CVD in SLE patients.
引用
收藏
页码:819 / 827
页数:9
相关论文
共 50 条
  • [31] IgM antibodies against malondialdehyde and phosphorylcholine are together strong protection markers for atherosclerosis in systemic lupus erythematosus: Regulation and underlying mechanisms
    Rahman, Mizanur
    Sing, Sudhir
    Golabkesh, Zahra
    Fiskesund, Roland
    Gustafsson, Thomas
    Jogestrand, Tomas
    Frostegard, Anna G.
    Hafstrom, Ingiald
    Liu, Anquan
    Frostegard, Johan
    CLINICAL IMMUNOLOGY, 2016, 166 : 27 - 37
  • [32] Atherosclerosis and renal disease involvement in patients with systemic lupus erythematosus: a cross-sectional cohort study
    Hermansen, Marie-Louise
    Sandholt, Benjamin
    Fuchs, Andreas
    Sillesen, Henrik
    Kober, Lars
    Kofoed, Klaus Fuglsang
    Faurschou, Mikkel
    Jacobsen, Soren
    RHEUMATOLOGY, 2018, 57 (11) : 1964 - 1971
  • [33] Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
    Avalos, I.
    Rho, Y. H.
    Chung, C. P.
    Stein, C. M.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2008, 26 (05) : S5 - S13
  • [34] Longitudinal study on premature atherosclerosis in patients with systemic lupus erythematosus
    de Leeuw, Karina
    Smit, Andries J.
    de Groot, Eric
    van Roon, Arie M.
    Kallenberg, Cees G.
    Bijl, Marc
    ATHEROSCLEROSIS, 2009, 206 (02) : 546 - 550
  • [35] Cystatin C is associated with inflammation but not atherosclerosis in systemic lupus erythematosus
    Lertnawapan, R.
    Bian, A.
    Rho, Y. H.
    Raggi, P.
    Oeser, A.
    Solus, J. F.
    Gebretsadik, T.
    Shintani, A.
    Stein, C. M.
    LUPUS, 2012, 21 (03) : 279 - 287
  • [36] Establishing a Risk Prediction Model for Atherosclerosis in Systemic Lupus Erythematosus
    Xing, Haiping
    Pang, Haiyu
    Du, Tian
    Yang, Xufei
    Zhang, Jing
    Li, Mengtao
    Zhang, Shuyang
    FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [37] Serum osteoprotegrin (OPG) in subclinical atherosclerosis in systemic lupus erythematosus
    Kiani, A. N.
    Aukrust, P.
    Ueland, T.
    Hollan, I.
    Barr, E.
    Magder, L. S.
    Petri, M.
    LUPUS, 2017, 26 (08) : 865 - 870
  • [38] Genetic variation and coronary atherosclerosis in patients with systemic lupus erythematosus
    Chung, C. P.
    Solus, J. F.
    Oeser, A.
    Li, C.
    Raggi, P.
    Smith, J. R.
    Stein, C. M.
    LUPUS, 2014, 23 (09) : 876 - 880
  • [39] Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis
    Park, Jin Kyun
    Kim, Jae-Yong
    Moon, Jin Young
    Ahn, Eun Young
    Lee, Eun Young
    Lee, Eun Bong
    Cho, Kyung-Hyun
    Song, Yeong Wook
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [40] Atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus
    Haque, Sahena
    Mirjafari, Hoda
    Bruce, Ian N.
    CURRENT OPINION IN LIPIDOLOGY, 2008, 19 (04) : 338 - 343